Vascular Biogenics Ltd. (NASDAQ:VBLT) is set to post its quarterly earnings results before the market opens on Monday, August 14th. Analysts expect Vascular Biogenics to post earnings of ($0.19) per share for the quarter.

Vascular Biogenics (NASDAQ:VBLT) last posted its earnings results on Monday, May 15th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by $0.02. On average, analysts expect Vascular Biogenics to post $-0.82 EPS for the current fiscal year and $-0.76 EPS for the next fiscal year.

Shares of Vascular Biogenics Ltd. (NASDAQ VBLT) opened at 4.05 on Monday. The company’s market cap is $108.97 million. Vascular Biogenics Ltd. has a 12-month low of $3.80 and a 12-month high of $6.70. The stock has a 50 day moving average of $4.46 and a 200 day moving average of $5.29.

A number of research analysts recently commented on VBLT shares. Zacks Investment Research upgraded Vascular Biogenics from a “sell” rating to a “hold” rating in a research report on Tuesday, May 16th. ValuEngine cut Vascular Biogenics from a “hold” rating to a “sell” rating in a research report on Tuesday, June 6th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $12.90.

TRADEMARK VIOLATION NOTICE: This piece was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/08/07/vascular-biogenics-ltd-vblt-scheduled-to-post-earnings-on-monday.html.

About Vascular Biogenics

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.

Earnings History for Vascular Biogenics (NASDAQ:VBLT)

Receive News & Ratings for Vascular Biogenics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.